Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.

Delve into advanced imaging and physiology-guided drug-coated balloon (DCB) strategies for complex coronary lesions. This session presents integrated approaches combining morphology and physiology, OCT guidance, and real-world cases highlighting DCB use in multivessel disease and calcified lesions.

From a clean puncture to a safe valvulotomy, a step by step video tour through performing distal radial MiniBAV – a novel technique.

Dejan Milasinovic provides his take on this clinical trial which was presented by Divaka Perera (London, United Kingdom), at the American College of Cardiology (ACC/WCC) 2023 Scientific Session.

Large-bore femoral access closure remains a critical step in transfemoral TAVI, where access-site complications can significantly impact outcomes.

This My Toolkit article presents a step-by-step tutorial on a combined suture- and plug-based closure strategy using one ProStyle™ and one Angio-Seal®. The technique aims to achieve rapid, reliable...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation.